Physician profile
James E Seely
NPI 1629065008
$2,793.83
in general payments reported to CMS, 2019-2025
17 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $356 · 2021: $360 · 2022: $441 · 2023: $193 · 2024: $549 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,149.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $512.40 | 2022-2024 | Jardiance |
| Lilly USA, LLC | $458.57 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $372.58 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $249.42 | 2024-2025 | Rexulti, Nuedexta |
| Bayer Healthcare Pharmaceuticals INC. | $125.01 | 2024 | |
| Glaxosmithkline, LLC. | $125.00 | 2021 | |
| Amgen INC. | $125.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2020 | |
| Eisai INC. | $125.00 | 2021 | |
| Dexcom, INC. | $119.96 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| E.R. Squibb & Sons, L.L.C. | $116.53 | 2020 | |
| Janssen Pharmaceuticals, INC | $94.35 | 2019 | |
| Novo Nordisk INC | $89.62 | 2019 | |
| Alkermes, INC. | $67.93 | 2023 | Vivitrol |
| Exact Sciences Corporation | $52.69 | 2024-2025 | Cologuard Collection Kit |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $17.83 | 2024 | Ingrezza |
| Ars Pharmaceuticals Operations, INC. | $16.94 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Seely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.